$2.03 Billion in Sales Expected for Zimmer Biomet Holdings, Inc. (ZBH) This Quarter

Wall Street analysts forecast that Zimmer Biomet Holdings, Inc. (NYSE:ZBH) will report sales of $2.03 billion for the current fiscal quarter, Zacks reports. Eleven analysts have made estimates for Zimmer Biomet’s earnings. The lowest sales estimate is $2.01 billion and the highest is $2.04 billion. Zimmer Biomet posted sales of $2.01 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1%. The firm is expected to report its next quarterly earnings results on Tuesday, January 30th.

On average, analysts expect that Zimmer Biomet will report full year sales of $2.03 billion for the current year, with estimates ranging from $7.76 billion to $7.83 billion. For the next fiscal year, analysts forecast that the business will post sales of $7.92 billion per share, with estimates ranging from $7.79 billion to $8.04 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Zimmer Biomet.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same period in the prior year, the company posted $1.79 earnings per share. The firm’s revenue for the quarter was down .8% compared to the same quarter last year.

A number of analysts have issued reports on the company. Morgan Stanley cut their target price on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a research note on Thursday, November 2nd. BMO Capital Markets cut their target price on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, November 2nd. Piper Jaffray Companies downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 2nd. SunTrust Banks, Inc. set a $136.00 target price on Zimmer Biomet and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Finally, Zacks Investment Research downgraded Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Zimmer Biomet has an average rating of “Hold” and an average target price of $133.71.

Zimmer Biomet (ZBH) traded down $0.03 during midday trading on Friday, reaching $113.07. The company had a trading volume of 289,061 shares, compared to its average volume of 1,510,000. Zimmer Biomet has a 1 year low of $99.11 and a 1 year high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. The firm has a market cap of $22,890.00, a P/E ratio of 14.01, a P/E/G ratio of 1.76 and a beta of 1.17.

Several large investors have recently modified their holdings of ZBH. Terra Nova Asset Management LLC increased its position in shares of Zimmer Biomet by 1.1% during the 2nd quarter. Terra Nova Asset Management LLC now owns 7,474 shares of the medical equipment provider’s stock worth $960,000 after purchasing an additional 79 shares during the last quarter. Rothschild Investment Corp IL increased its position in shares of Zimmer Biomet by 11.3% during the 2nd quarter. Rothschild Investment Corp IL now owns 69,574 shares of the medical equipment provider’s stock worth $8,933,000 after purchasing an additional 7,090 shares during the last quarter. Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in shares of Zimmer Biomet during the 2nd quarter worth about $1,656,000. Altfest L J & Co. Inc. acquired a new stake in shares of Zimmer Biomet during the 2nd quarter worth about $654,000. Finally, Hermes Investment Management Ltd. acquired a new stake in shares of Zimmer Biomet during the 2nd quarter worth about $611,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

WARNING: “$2.03 Billion in Sales Expected for Zimmer Biomet Holdings, Inc. (ZBH) This Quarter” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://transcriptdaily.com/2017/11/26/2-03-billion-in-sales-expected-for-zimmer-biomet-holdings-inc-zbh-this-quarter.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply